Leadership

Functional areas are supported by experts in the field, each with decades of experience developing major products—including many well-recognized medicines on the market generating sales of up to $6B annually.

The wider team and leadership hold extensive hands-on experience in drug development to help biotech companies navigate the journey to successful drug registration and take on challenges that require innovative approaches.

Our team

Leadership

Parviz Ghahramani CEO & Founder

Parviz Ghahramani

Parviz Ghahramani holds a Ph.D. in Clinical Pharmacology, Pharm.D, M.Sc. in Statistics and MBA. With over 26 years of drug development experience, Dr. Ghahramani specializes in clinical pharmacology, pharmacokinetics, modeling and simulation.

He has a proven track record of executive leadership and strategy roles within major pharma companies, including Pfizer, Roche, AstraZeneca and Abbvie (formerly Forest Laboratories).

Ghahramani has led or overseen more than 86 drug development projects across various stages, ranging from small molecules to biologics and antibodies. He has made major contributions to 31 NDAs, MAAs and JNDAs, and to more than 308 licensing and acquisition assessments and company mergers.

He has published more than 130 academic papers in reputable international journals and is an affiliate professor at the University of Maryland.

Dr. Stephen A. Barat Head of Pre-Clinical

Dr. Stephen A. Barat

Barat studied at Rutgers University and New Jersey Medical School, earning a Ph.D. in Pharmacology and Toxicology.

He holds 30 years of large pharma and biotech drug development experience, from subject matter expert to product development team leader. He has held senior and executive leadership positions within Schering-Plough (Merck), Forest Laboratories, Scynexis and Janssen.

Barat has contributed to the selection, development and regulatory approval of 15 new drug products across multiple therapeutic areas and routes of administration, with significant regulatory agency experience in the United States, Europe and Japan.

He has expertise in the interface between CMC and safety assessment and drug packaging, and has been an active member of industry working groups with USP, PDA and PQRI. He is a course creator and faculty for ACT and DIA.